JP2006503001A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006503001A5 JP2006503001A5 JP2004525322A JP2004525322A JP2006503001A5 JP 2006503001 A5 JP2006503001 A5 JP 2006503001A5 JP 2004525322 A JP2004525322 A JP 2004525322A JP 2004525322 A JP2004525322 A JP 2004525322A JP 2006503001 A5 JP2006503001 A5 JP 2006503001A5
- Authority
- JP
- Japan
- Prior art keywords
- erythropoietin
- use according
- epo
- pharmaceutical composition
- progenitor cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 44
- 102000003951 Erythropoietin Human genes 0.000 claims 24
- 108090000394 Erythropoietin Proteins 0.000 claims 24
- 230000003511 endothelial effect Effects 0.000 claims 24
- 229940105423 erythropoietin Drugs 0.000 claims 24
- 108010092408 Eosinophil Peroxidase Proteins 0.000 claims 20
- 102100031939 Erythropoietin Human genes 0.000 claims 20
- 210000000130 stem cell Anatomy 0.000 claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 230000037396 body weight Effects 0.000 claims 10
- 230000003442 weekly effect Effects 0.000 claims 10
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 8
- 210000001519 tissue Anatomy 0.000 claims 8
- 239000004480 active ingredient Substances 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 7
- 230000000638 stimulation Effects 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 230000004064 dysfunction Effects 0.000 claims 6
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 6
- 230000033115 angiogenesis Effects 0.000 claims 5
- 230000015572 biosynthetic process Effects 0.000 claims 5
- 210000004204 blood vessel Anatomy 0.000 claims 5
- 210000002889 endothelial cell Anatomy 0.000 claims 5
- 201000011461 pre-eclampsia Diseases 0.000 claims 5
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 4
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 claims 4
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 claims 4
- 102100035194 Placenta growth factor Human genes 0.000 claims 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 4
- 208000020832 chronic kidney disease Diseases 0.000 claims 4
- 210000003038 endothelium Anatomy 0.000 claims 4
- 230000001771 impaired effect Effects 0.000 claims 4
- 239000002840 nitric oxide donor Substances 0.000 claims 4
- 210000000056 organ Anatomy 0.000 claims 4
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 3
- 229930064664 L-arginine Natural products 0.000 claims 3
- 235000014852 L-arginine Nutrition 0.000 claims 3
- 208000003782 Raynaud disease Diseases 0.000 claims 3
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 3
- 208000033626 Renal failure acute Diseases 0.000 claims 3
- 206010038802 Reticuloendothelial system stimulated Diseases 0.000 claims 3
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 3
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims 3
- 201000011040 acute kidney failure Diseases 0.000 claims 3
- 208000012998 acute renal failure Diseases 0.000 claims 3
- 229960005370 atorvastatin Drugs 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 208000037976 chronic inflammation Diseases 0.000 claims 3
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 210000003709 heart valve Anatomy 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 230000000302 ischemic effect Effects 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims 3
- 229950009116 mevastatin Drugs 0.000 claims 3
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 229960002855 simvastatin Drugs 0.000 claims 3
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 3
- 230000029663 wound healing Effects 0.000 claims 3
- 206010070538 Gestational hypertension Diseases 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 230000002491 angiogenic effect Effects 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 210000002700 urine Anatomy 0.000 claims 2
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 238000012270 DNA recombination Methods 0.000 claims 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 claims 1
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 230000007910 cell fusion Effects 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 208000028208 end stage renal disease Diseases 0.000 claims 1
- 201000000523 end stage renal failure Diseases 0.000 claims 1
- 102000044890 human EPO Human genes 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 230000007115 recruitment Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000009772 tissue formation Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10234192A DE10234192B4 (de) | 2002-07-26 | 2002-07-26 | Verwendung von Erythropoetin |
| DE10234192.3 | 2002-07-26 | ||
| PCT/EP2003/008229 WO2004012759A2 (de) | 2002-07-26 | 2003-07-25 | Erythropoetin zur stimulation endothelialer voläuferzellen |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010157093A Division JP2010280671A (ja) | 2002-07-26 | 2010-07-09 | エリスロポエチンの使用 |
| JP2010157094A Division JP2010280672A (ja) | 2002-07-26 | 2010-07-09 | エリスロポエチンの使用 |
| JP2010157092A Division JP2010280670A (ja) | 2002-07-26 | 2010-07-09 | エリスロポエチンの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006503001A JP2006503001A (ja) | 2006-01-26 |
| JP2006503001A5 true JP2006503001A5 (https=) | 2006-06-15 |
| JP4727988B2 JP4727988B2 (ja) | 2011-07-20 |
Family
ID=30128436
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004525322A Expired - Fee Related JP4727988B2 (ja) | 2002-07-26 | 2003-07-25 | エリスロポエチンの使用 |
| JP2010157093A Withdrawn JP2010280671A (ja) | 2002-07-26 | 2010-07-09 | エリスロポエチンの使用 |
| JP2010157094A Withdrawn JP2010280672A (ja) | 2002-07-26 | 2010-07-09 | エリスロポエチンの使用 |
| JP2010157092A Withdrawn JP2010280670A (ja) | 2002-07-26 | 2010-07-09 | エリスロポエチンの使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010157093A Withdrawn JP2010280671A (ja) | 2002-07-26 | 2010-07-09 | エリスロポエチンの使用 |
| JP2010157094A Withdrawn JP2010280672A (ja) | 2002-07-26 | 2010-07-09 | エリスロポエチンの使用 |
| JP2010157092A Withdrawn JP2010280670A (ja) | 2002-07-26 | 2010-07-09 | エリスロポエチンの使用 |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US7745387B2 (https=) |
| EP (3) | EP2191838A1 (https=) |
| JP (4) | JP4727988B2 (https=) |
| KR (2) | KR20100077033A (https=) |
| CN (3) | CN1681526A (https=) |
| AT (2) | ATE360436T1 (https=) |
| AU (2) | AU2003255290B2 (https=) |
| BR (1) | BR0312981A (https=) |
| CA (2) | CA2493598A1 (https=) |
| CY (2) | CY1108052T1 (https=) |
| DE (3) | DE10234192B4 (https=) |
| DK (2) | DK1526867T3 (https=) |
| EA (3) | EA200801236A1 (https=) |
| ES (2) | ES2345673T3 (https=) |
| HR (3) | HRP20100187A2 (https=) |
| IL (2) | IL166401A0 (https=) |
| IS (3) | IS2671B (https=) |
| MX (1) | MXPA05001120A (https=) |
| NO (1) | NO20051002L (https=) |
| PL (2) | PL374874A1 (https=) |
| PT (2) | PT1526867E (https=) |
| SG (1) | SG177004A1 (https=) |
| SI (2) | SI1779862T1 (https=) |
| UA (2) | UA85997C2 (https=) |
| WO (1) | WO2004012759A2 (https=) |
| ZA (1) | ZA200500726B (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7723303B2 (en) | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| US7199102B2 (en) | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| DE10234192B4 (de) | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
| WO2005014023A1 (en) * | 2003-07-29 | 2005-02-17 | Dompe' Pha.R.Ma S.P.A. | Pharmaceutical combination of g-csf and plgf useful for blood stem cell |
| ATE469654T1 (de) * | 2003-12-30 | 2010-06-15 | Augustinus Bader | Verwendung des erythropoietins zur regeneration von lebergewebe |
| DE102004004509B4 (de) * | 2004-01-23 | 2010-07-01 | Epoplus Gmbh Co.Kg | Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden |
| KR20070089996A (ko) | 2004-12-06 | 2007-09-04 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 세동맥의 구조 및 기능의 개선 방법 |
| AR053416A1 (es) | 2005-11-10 | 2007-05-09 | Protech Pharma S A | Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac |
| ES2649983T3 (es) | 2005-11-23 | 2018-01-16 | Acceleron Pharma, Inc. | Antagonistas de activina-ActRIIa en su uso para promover el crecimiento óseo |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| BRPI0712063A2 (pt) * | 2006-06-07 | 2011-12-20 | Chugai Pharmaceutical Co Ltd | tratamento de doenças isquêmicas usando eritropoietina |
| MX2009003441A (es) * | 2006-09-29 | 2009-10-16 | Centocor Ortho Biotech Inc | Agonistas del receptor de eritropoyetina humana, composiciones, metodos y usos para prevenir o tratar condiciones relacionadas con la intolerancia a la glucosa. |
| JP5676849B2 (ja) | 2006-10-20 | 2015-02-25 | 中外製薬株式会社 | 抗ｈｂ−ｅｇｆ抗体を有効成分として含む癌治療剤 |
| EP3040347A3 (en) * | 2006-10-20 | 2016-09-21 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient |
| US8975374B2 (en) * | 2006-10-20 | 2015-03-10 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| WO2008086025A2 (en) * | 2007-01-10 | 2008-07-17 | Edison Pharmaceuticals, Inc. | Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity |
| TW201803890A (zh) | 2007-02-02 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| AR065613A1 (es) * | 2007-03-09 | 2009-06-17 | Chugai Pharmaceutical Co Ltd | Agentes de proteccion para organos transplantados |
| WO2009022338A2 (en) | 2007-08-16 | 2009-02-19 | Saher Hamed | Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications |
| US20090291092A1 (en) * | 2008-05-22 | 2009-11-26 | Miller Guy M | Treatment of mitochondrial diseases with an erythropoietin mimetic |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| TW201803586A (zh) | 2008-08-14 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| KR20120049214A (ko) | 2009-06-08 | 2012-05-16 | 악셀레론 파마 인코포레이티드 | 발열성 지방세포를 증가시키는 방법 |
| KR20180026795A (ko) | 2009-06-12 | 2018-03-13 | 악셀레론 파마 인코포레이티드 | 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질 |
| AU2010282361B2 (en) * | 2009-08-13 | 2015-03-19 | Acceleron Pharma Inc. | Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels |
| EP3332796A1 (en) | 2009-11-17 | 2018-06-13 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| WO2012003960A1 (en) | 2010-07-06 | 2012-01-12 | Augustinus Bader | Topical application of erythropoietin for the treatment of eye disorders and injuries |
| WO2012148200A2 (ko) * | 2011-04-26 | 2012-11-01 | 아주대학교 산학협력단 | 허혈성 혈관 질환 치료시술 보조용 조성물 |
| US10195249B2 (en) | 2012-11-02 | 2019-02-05 | Celgene Corporation | Activin-ActRII antagonists and uses for treating bone and other disorders |
| US8992951B2 (en) | 2013-01-09 | 2015-03-31 | Sapna Life Sciences Corporation | Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma |
| US20160279297A1 (en) * | 2013-10-22 | 2016-09-29 | ConcieValve LLC | Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis |
| CN114699529A (zh) | 2014-06-13 | 2022-07-05 | 阿塞勒隆制药公司 | 用于治疗溃疡的方法和组合物 |
| CA2976376A1 (en) * | 2015-02-13 | 2016-08-18 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| CN105233256A (zh) * | 2015-10-28 | 2016-01-13 | 中国人民解放军第三军医大学 | 促红细胞生成素及其衍生物在制备治疗疾病中促进凋亡细胞清除的药物中的应用 |
| US11534466B2 (en) * | 2016-03-09 | 2022-12-27 | Aal Scientifics, Inc. | Pancreatic stem cells and uses thereof |
| GB2550114A (en) * | 2016-05-03 | 2017-11-15 | Kymab Ltd | Methods, regimens, combinations & antagonists |
| IL308824A (en) | 2016-08-17 | 2024-01-01 | Factor Bioscience Inc | Nucleic acid products and methods of administration thereof |
| CN108114282B (zh) * | 2016-11-28 | 2021-03-02 | 北京大学第三医院 | 他汀类化合物治疗缺血性疾病的用途 |
| WO2018203545A1 (ja) | 2017-05-02 | 2018-11-08 | 国立研究開発法人国立精神・神経医療研究センター | Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法 |
| JP7235249B2 (ja) * | 2017-10-20 | 2023-03-08 | 学校法人兵庫医科大学 | 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物 |
| WO2019151418A1 (ja) | 2018-01-31 | 2019-08-08 | 元一 加藤 | Ｉｌ－６阻害剤を含有する喘息の治療剤 |
| RU2695334C1 (ru) * | 2018-09-25 | 2019-07-23 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ профилактики нарушений функций почек карбамилированным дарбэпоэтином в эксперименте |
| RU2678768C1 (ru) * | 2018-09-25 | 2019-02-01 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ профилактики ишемически-реперфузионных повреждений почек карбамилированным дарбэпоэтином в эксперименте |
| EP3957324A4 (en) | 2019-04-17 | 2023-02-08 | Hiroshima University | THERAPEUTIC FOR UROLOGICAL ONCOLOGY CHARACTERIZED BY BEING ADMINISTRATED IN COMBINATION WITH IL-6 INHIBITOR AND CCR2 INHIBITOR |
| CA3145425A1 (en) | 2019-07-03 | 2021-01-07 | Factor Bioscience Inc. | Cationic lipids and uses thereof |
| US10501404B1 (en) | 2019-07-30 | 2019-12-10 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
| CA3193654A1 (en) | 2020-10-02 | 2022-04-07 | Jasbir S. Seehra | Methods of using activin receptor type ii variants |
| CN119080909A (zh) * | 2024-08-29 | 2024-12-06 | 深圳赛保尔生物药业有限公司 | 负载peg-epo及间充质干细胞的组合物、药物及其制备方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| IL77081A (en) | 1984-12-04 | 1999-10-28 | Genetics Inst | Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin |
| US4732889A (en) | 1985-02-06 | 1988-03-22 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis |
| JPH0764742B2 (ja) | 1985-11-27 | 1995-07-12 | ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド | Ａｉｄｓ型疾患治療用組成物 |
| US5198417A (en) * | 1985-11-27 | 1993-03-30 | Genetics Institute, Inc. | Methods of treating pancytopenia and AIDS by co-administering EPO and colony stimulating factors |
| DK173067B1 (da) | 1986-06-27 | 1999-12-13 | Univ Washington | Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa |
| US5013718A (en) | 1986-11-21 | 1991-05-07 | Amgen, Inc. | Method for treating iron overload using EPO |
| DE3729863A1 (de) * | 1987-09-05 | 1989-03-16 | Boehringer Mannheim Gmbh | Stabilisierte erythropoietin-lyophilisate |
| JPH03503167A (ja) * | 1988-02-24 | 1991-07-18 | アメリカン ナショナル レッド クロス | 部位指定血管形成素子とその使用法 |
| US5024841A (en) * | 1988-06-30 | 1991-06-18 | Collagen Corporation | Collagen wound healing matrices and process for their production |
| DE4014654A1 (de) | 1990-05-08 | 1991-11-14 | Behringwerke Ag | Galenische waessrige formulierungen von erythropoietin und ihre verwendung |
| DK0575555T3 (da) * | 1991-03-11 | 2001-11-05 | Curis Inc | Proteininduceret morfogenese |
| US5354934A (en) * | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
| BR9406490A (pt) | 1993-04-29 | 1996-03-05 | Abbott Lab | Análogo de eritropoietina humana,DNA de filamento duplo,vetor de expressão célula de mamiferos em cultura composição farmaceutica segundo e terceiro análogo de eritropoietina humana e processos para fabricar um segundo análogo de eritropoietina e para usar um segundo análogo |
| CN1057534C (zh) | 1993-08-17 | 2000-10-18 | 柯瑞英-艾格公司 | 促红细胞生成素类似物 |
| JPH08205860A (ja) * | 1994-01-21 | 1996-08-13 | Usa Government | 造血細胞の膨大化および移植方法 |
| ITFI940106A1 (it) * | 1994-05-27 | 1995-11-27 | Menarini Ricerche Sud Spa | Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica |
| ATE251912T1 (de) | 1994-11-03 | 2003-11-15 | Roche Diagnostics Gmbh | Verwendung des erythropoietins zur behandlung von rheumatoider arthritis |
| US5837675A (en) | 1995-02-03 | 1998-11-17 | Brox; Alan G. | Synergistic effect of insulin-like growth factor-I and erythropoietin |
| US20020052309A1 (en) * | 1996-09-11 | 2002-05-02 | Athanasius A. Anagnostou | Method of treating endothelial injury |
| US5980887A (en) * | 1996-11-08 | 1999-11-09 | St. Elizabeth's Medical Center Of Boston | Methods for enhancing angiogenesis with endothelial progenitor cells |
| US6274158B1 (en) * | 1998-02-04 | 2001-08-14 | Veronica L. Zaharia Czeizler | Treatment with recombinant human erythropoietin of bleeding in patients with normal and abnormal hemostasis |
| US6284260B1 (en) | 1998-02-04 | 2001-09-04 | Veronica L. Zaharia Czeizler | Treatment with erythropoietin of bleeding from benign and malignant lesions with normal and abnormal coagulation parameters |
| DE19857609A1 (de) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
| KR101012932B1 (ko) * | 1999-04-13 | 2011-02-08 | 더 케네쓰 에스. 워렌 인스티튜트 인코포레이티드 | 말초 투여된 에리트로포에틴에 의한 흥분조직의 기능조절법 |
| AU2001254625B2 (en) | 2000-05-02 | 2006-02-02 | Action Pharma A/S | Use of alpha-MSH and EPO for preventing or treating ischemic conditions |
| US7259146B2 (en) * | 2000-05-26 | 2007-08-21 | Ortho-Mcneil Pharmaceutical, Inc. | Neuroprotective peptides |
| US7078376B1 (en) * | 2000-08-11 | 2006-07-18 | Baxter Healthcare S.A. | Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
| US20020065214A1 (en) * | 2000-11-29 | 2002-05-30 | Adrian Iaina | Method of treating congestive heart failure |
| PA8536201A1 (es) | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
| CA2443373A1 (en) * | 2001-04-04 | 2002-10-31 | Genodyssee | New polynucleotides and polypeptides of the erythropoietin gene |
| US6784154B2 (en) * | 2001-11-01 | 2004-08-31 | University Of Utah Research Foundation | Method of use of erythropoietin to treat ischemic acute renal failure |
| WO2003045423A1 (en) * | 2001-11-28 | 2003-06-05 | Ortho-Mcneil Pharmaceutical, Inc. | Erythropoietin dosing regimen for treating anemia |
| CN1612747A (zh) * | 2002-01-09 | 2005-05-04 | 克鲁塞尔荷兰公司 | 促红细胞生成素在预防或治疗心力衰竭中的用途 |
| US6748154B2 (en) * | 2002-03-28 | 2004-06-08 | Nortel Networks Limited | Optical module access tray |
| DE10234192B4 (de) * | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
| DE102004004509B4 (de) * | 2004-01-23 | 2010-07-01 | Epoplus Gmbh Co.Kg | Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden |
-
2002
- 2002-07-26 DE DE10234192A patent/DE10234192B4/de not_active Expired - Fee Related
-
2003
- 2003-07-25 KR KR1020107011097A patent/KR20100077033A/ko not_active Ceased
- 2003-07-25 EA EA200801236A patent/EA200801236A1/ru unknown
- 2003-07-25 EP EP10000381A patent/EP2191838A1/de not_active Withdrawn
- 2003-07-25 UA UAA200501760A patent/UA85997C2/ru unknown
- 2003-07-25 JP JP2004525322A patent/JP4727988B2/ja not_active Expired - Fee Related
- 2003-07-25 EA EA200500281A patent/EA009463B1/ru not_active IP Right Cessation
- 2003-07-25 PL PL03374874A patent/PL374874A1/xx unknown
- 2003-07-25 PL PL395151A patent/PL395151A1/pl unknown
- 2003-07-25 DE DE50307140T patent/DE50307140D1/de not_active Expired - Lifetime
- 2003-07-25 DK DK03766302T patent/DK1526867T3/da active
- 2003-07-25 CA CA002493598A patent/CA2493598A1/en not_active Abandoned
- 2003-07-25 HR HR20100187A patent/HRP20100187A2/xx not_active Application Discontinuation
- 2003-07-25 MX MXPA05001120A patent/MXPA05001120A/es active IP Right Grant
- 2003-07-25 SG SG2007003890A patent/SG177004A1/en unknown
- 2003-07-25 KR KR1020057001341A patent/KR20050026513A/ko not_active Ceased
- 2003-07-25 WO PCT/EP2003/008229 patent/WO2004012759A2/de not_active Ceased
- 2003-07-25 EP EP07001689A patent/EP1779862B1/de not_active Expired - Lifetime
- 2003-07-25 CN CNA038221160A patent/CN1681526A/zh active Pending
- 2003-07-25 AT AT03766302T patent/ATE360436T1/de not_active IP Right Cessation
- 2003-07-25 EP EP03766302A patent/EP1526867B1/de not_active Expired - Lifetime
- 2003-07-25 CN CN200710127913XA patent/CN101099731B/zh not_active Expired - Fee Related
- 2003-07-25 SI SI200331837T patent/SI1779862T1/sl unknown
- 2003-07-25 UA UAA200801307A patent/UA94913C2/ru unknown
- 2003-07-25 US US10/522,426 patent/US7745387B2/en not_active Expired - Fee Related
- 2003-07-25 PT PT03766302T patent/PT1526867E/pt unknown
- 2003-07-25 DK DK07001689.4T patent/DK1779862T3/da active
- 2003-07-25 ES ES07001689T patent/ES2345673T3/es not_active Expired - Lifetime
- 2003-07-25 DE DE50312729T patent/DE50312729D1/de not_active Expired - Lifetime
- 2003-07-25 PT PT07001689T patent/PT1779862E/pt unknown
- 2003-07-25 CN CN2007101279144A patent/CN101099860B/zh not_active Expired - Fee Related
- 2003-07-25 CA CA2710100A patent/CA2710100A1/en not_active Abandoned
- 2003-07-25 AU AU2003255290A patent/AU2003255290B2/en not_active Ceased
- 2003-07-25 HR HR20050065A patent/HRP20050065A2/hr not_active Application Discontinuation
- 2003-07-25 HR HR20070189A patent/HRP20070189A2/xx not_active Application Discontinuation
- 2003-07-25 EA EA200700196A patent/EA013966B1/ru not_active IP Right Cessation
- 2003-07-25 BR BR0312981-0A patent/BR0312981A/pt not_active IP Right Cessation
- 2003-07-25 ES ES03766302T patent/ES2285195T3/es not_active Expired - Lifetime
- 2003-07-25 AT AT07001689T patent/ATE468132T1/de not_active IP Right Cessation
- 2003-07-25 SI SI200330881T patent/SI1526867T1/sl unknown
-
2005
- 2005-01-06 IS IS7633A patent/IS2671B/is unknown
- 2005-01-20 IL IL16640105A patent/IL166401A0/xx not_active IP Right Cessation
- 2005-01-25 ZA ZA200500726A patent/ZA200500726B/xx unknown
- 2005-02-24 NO NO20051002A patent/NO20051002L/no not_active Application Discontinuation
-
2007
- 2007-07-02 CY CY20071100871T patent/CY1108052T1/el unknown
-
2009
- 2009-02-25 AU AU2009200748A patent/AU2009200748A1/en not_active Abandoned
- 2009-05-06 IS IS8817A patent/IS8817A/is unknown
-
2010
- 2010-03-18 IL IL204577A patent/IL204577A/en not_active IP Right Cessation
- 2010-04-13 US US12/759,321 patent/US20100247452A1/en not_active Abandoned
- 2010-04-13 US US12/759,275 patent/US20100247450A1/en not_active Abandoned
- 2010-04-13 US US12/759,299 patent/US20100247451A1/en not_active Abandoned
- 2010-07-02 IS IS8909A patent/IS8909A/is unknown
- 2010-07-09 JP JP2010157093A patent/JP2010280671A/ja not_active Withdrawn
- 2010-07-09 JP JP2010157094A patent/JP2010280672A/ja not_active Withdrawn
- 2010-07-09 JP JP2010157092A patent/JP2010280670A/ja not_active Withdrawn
- 2010-07-29 CY CY20101100712T patent/CY1110713T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006503001A5 (https=) | ||
| WO2004012759B1 (de) | Erythropoetin zur stimulation endothelialer voläuferzellen | |
| JP2025024101A (ja) | 幹細胞由来エクソソーム生成促進及び幹細胞能増強用組成物 | |
| JP2010235613A (ja) | 内皮前駆細胞の刺激並びに臓器の再生及び内臓障害の進行の抑制のための低用量エリスロポエチンの使用 | |
| US11351190B2 (en) | Composition for treating tissue lesions | |
| KR20060079753A (ko) | 혈액 줄기 세포의 동원에 유효한 ｇ-ｃｓｆ와 ｐｌｇｆ의조합 약제 | |
| Li et al. | Pravastatin improves remodeling and cardiac function after myocardial infarction by an antiinflammatory mechanism rather than by the induction of angiogenesis | |
| AU2021410513A9 (en) | Stem cell priming composition and primed stem cell | |
| RU2248216C2 (ru) | Композиция и способ увеличения количества стволовых клеток и/или гематопоэтических клеток-предшественников в циркуляции в периферической крови млекопитающих | |
| US20200061124A1 (en) | Methods for making and using dedifferentiated and stem-like human cells | |
| US20250002580A1 (en) | Method for inhibiting cardiac fibroblast transdifferentiation | |
| KR20180024877A (ko) | 인간 잇몸-유래 줄기세포 및 골전구체 세포를 공동배양하여 형성된 세포 스페로이드 및 이로부터 혈관내피 성장인자의 생산량을 증가시키는 방법 | |
| JP2005522490A (ja) | Ｐｔｘ３遺伝子発現抑制方法 | |
| CN114129565A (zh) | 组蛋白甲基转移酶ezh2抑制剂在促使骨代谢进入高转换以修复骨缺损产品中的应用 | |
| JP6814925B2 (ja) | Ｈｇｆ誘導剤 | |
| Injarabian et al. | 526 Macrophage cell death instructs fibroblast-repair functions in skin wound healing | |
| Mataix et al. | 525 Aptamer-Based Targeted Therapy for wound healing and hair growth promotion | |
| Marjanovic et al. | 527 PTEN is a master driver of healing inhibition in venous leg ulcers by targeting immune response, angiogenesis and lymphangiogenesis | |
| Matar et al. | 528 Serotonin modulation improves cutaneous wound healing | |
| Park et al. | Cytotoxicities and Anti-Fibrotic Effects of Pirfenidone and Mitomycin C on Human Fibroblasts | |
| KR101986092B1 (ko) | 유두진피 섬유아세포의 고순도 분리 방법 | |
| HK1139072A (en) | Use of low-dose erythropoietin for the treatment of acute or chronic renal insufficiency and for the treatment of wounds | |
| HK1139866A (en) | Erythropoetin for the stimulation of endothelial precursor cells | |
| CN114569596A (zh) | 一类用于促进组织细胞再生的药物 | |
| JP2003073300A (ja) | 造血前駆細胞動員増強剤 |